NY-ESO-1-specific TIM biologic - Tavotek Biotherapeutics
Alternative Names: NY-ESO-1-specific TIM molecule - Tavotek BiotherapeuticsLatest Information Update: 28 Jun 2024
At a glance
- Originator Tavotek Biotherapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 29 May 2020 NY-ESO-1-specific TIM biologic - Tavotek Biotherapeutics is available for licensing as of 29 May 2020. www.tavotek.com
- 29 May 2020 Pharmacodynamics data from a study in Solid tumours presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)